An Open-Label Extension of Study HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Intrathecal Idursulfase-IT Administered in Conjunction With Intravenous Elaprase® in Pediatric Patients With Hunter Syndrome and Cognitive Impairment

Vivli 2026 Dataset Open access

Read full text
Authors: Takeda
DOI: 10.25934/pr00012657
Cited by: 0

Abstract

This extension study of HGT-HIT-045 is designed to collect long-term safety data in pediatric participants with Hunter syndrome and cognitive impairment who are receiving intrathecal (IT) idursulfase-IT and intravenous (IV) Elaprase enzyme replacement therapy.

Fields of Study & Subjects

Lysosomal Storage Disorders Research Glycogen Storage Diseases and Myoclonus Genetic Neurodegenerative Diseases

Publication details

Journal / source
Vivli
Publication date
13 January 2026
Language
EN
Document type
Dataset